A potential biomarker of radiosensitivity in metastatic hormone sensitive prostate cancer patients treated with combination external beam radiotherapy and radium-223
Prostate cancer is the second most common cancer in men worldwide, with more than 1 million cases diagnosed annually, and is the fifth most common cause of death in men [1]. Treatment options for prostate cancer depend on the stage of the disease at diagnosis and include hormone therapy, surgery, chemotherapy and various radiotherapy techniques, including external beam radiotherapy (EBRT), brachytherapy and radionuclide therapy [2]. Bone metastases are common in advanced prostate cancer patients, with up to 10% of newly diagnosed patients presenting with bone metastases [3,4].
Source: Radiotherapy and Oncology - Category: Radiology Authors: K.M. Redmond, P.G. Turner, A. Cole, S. Jain, K.M. Prise, J.M. O'Sullivan Tags: Original Article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Chemotherapy | External Beam Therapy | Hormonal Therapy | Hormones | Prostate Cancer | Radiology